New product: Vocabria (cabotegravir) 600 mg prolonged-release suspension for injection
This is licensed for use in combination with rilpivirine injection for the treatment of virologically suppressed adults on a stable antiretroviral regimen without present or past evidence of viral resistance to, & no prior virological failure with agents of the NNRTI & INI class
Source:
electronic Medicines compendium
SPS commentary:
Oral cabotegravir (Vocabria film-coated tablets) has also been licensed; this should be taken together with oral rilpivirine for approximately one month (at least 28 days) prior to the initiation of Vocabria injection, to assess tolerability to cabotegravir and rilpivirine.